Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

Relationship of P-Selectin Glycoprotein Ligand-1 to Prognosis in Patients With Multiple Myeloma

(2015) Figen Atalay et al.   Clinical Lymphoma Myeloma & Leukemia

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

(2012) Y Zheng et al.   LEUKEMIA

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment

(2011) A. K. Azab et al.   BLOOD

FGFR3 Is Overexpressed Waldenstrom Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation

(2011) A. K. Azab et al.   CLINICAL CANCER RESEARCH

Interactions between endothelial selectins and cancer cells regulate metastasis

(2011) Catherine A. et al.   Frontiers in Bioscience-Landmark

GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice

(2010) J. Chang et al.   BLOOD

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma

(2009) A. K. Azab et al.   BLOOD

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)

(2009) C. Tripodo et al.   CURRENT CANCER DRUG TARGETS

The selectin–selectin ligand axis in tumor progression

(2008) Isaac P. Witz   CANCER AND METASTASIS REVIEWS